• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neoadjuvant chemotherapy for breast cancer: any progress?

作者信息

Colleoni Marco, Goldhirsch Aron

机构信息

International Breast Cancer Study Group and Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy.

International Breast Cancer Study Group and Breast Health Program, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy.

出版信息

Lancet Oncol. 2014 Feb;15(2):131-2. doi: 10.1016/S1470-2045(13)70584-9. Epub 2013 Dec 19.

DOI:10.1016/S1470-2045(13)70584-9
PMID:24360786
Abstract
摘要

相似文献

1
Neoadjuvant chemotherapy for breast cancer: any progress?乳腺癌的新辅助化疗：有进展吗？
Lancet Oncol. 2014 Feb;15(2):131-2. doi: 10.1016/S1470-2045(13)70584-9. Epub 2013 Dec 19.
2
Neoadjuvant chemotherapy for operable breast cancer: individualizing locoregional and systemic therapy.可手术乳腺癌的新辅助化疗：局部区域和全身治疗的个体化
Surg Oncol Clin N Am. 2010 Jul;19(3):607-26. doi: 10.1016/j.soc.2010.04.001.
3
Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer.洞察还是困惑：乳腺癌中反应引导的新辅助化疗后的生存情况
J Clin Oncol. 2013 Oct 10;31(29):3613-5. doi: 10.1200/JCO.2013.51.0313. Epub 2013 Sep 3.
4
[Neoadjuvant systemic chemotherapy for patients with operable breast cancer].[可手术乳腺癌患者的新辅助全身化疗]
Zhonghua Zhong Liu Za Zhi. 2007 Mar;29(3):161-5.
5
[Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with breast cancer].[乳腺癌患者新辅助化疗后的前哨淋巴结活检]
Nihon Rinsho. 2007 Jun 28;65 Suppl 6:198-201.
6
Node micrometastases detection after neoadjuvant chemotherapy in breast cancer: is it of clinical value?新辅助化疗后乳腺癌中微转移灶的检测：具有临床价值吗？
Ann Surg Oncol. 2010 Mar;17(3):933-4; author reply 935. doi: 10.1245/s10434-009-0746-4. Epub 2009 Oct 15.
7
The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis.乳腺癌的激素受体状态可通过新辅助化疗改变：一项荟萃分析。
Cancer Invest. 2011 Nov;29(9):594-8. doi: 10.3109/07357907.2011.621913.
8
[Application of neoadjuvant chemotherapy for operable breast cancer].[新辅助化疗在可手术乳腺癌中的应用]
Nan Fang Yi Ke Da Xue Xue Bao. 2009 Dec;29(12):2510-1.
9
Appropriate role for sentinel node biopsy after neoadjuvant chemotherapy in patients with early-stage breast cancer.新辅助化疗后前哨淋巴结活检在早期乳腺癌患者中的恰当作用。
J Clin Oncol. 2015 Jan 20;33(3):232-4. doi: 10.1200/JCO.2014.58.9838. Epub 2014 Dec 8.
10
How addition of capecitabine might be more beneficial in the neoadjuvant treatment of breast cancer.在乳腺癌新辅助治疗中，添加卡培他滨可能如何更有益。
J BUON. 2011 Apr-Jun;16(2):377.

引用本文的文献

1
Molecular shifts in breast cancer following neoadjuvant chemotherapy: a prospective study and review of literature.新辅助化疗后乳腺癌的分子变化：一项前瞻性研究及文献综述
Future Oncol. 2025 Apr;21(10):1209-1218. doi: 10.1080/14796694.2025.2475729. Epub 2025 Mar 24.
2
Automated Breast Ultrasound for Evaluating Response to Neoadjuvant Therapy: A Comparison with Magnetic Resonance Imaging.用于评估新辅助治疗反应的自动乳腺超声：与磁共振成像的比较
J Pers Med. 2024 Aug 31;14(9):930. doi: 10.3390/jpm14090930.
3
Contrast-Enhanced Spectral Mammography Assessment of Patients Treated with Neoadjuvant Chemotherapy for Breast Cancer.
对比增强光谱乳腺摄影评估接受新辅助化疗的乳腺癌患者。
Curr Oncol. 2021 Sep 6;28(5):3448-3462. doi: 10.3390/curroncol28050298.
4
The diagnostic performance of CESM and CE-MRI in evaluating the pathological response to neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.对比增强乳腺X线摄影（CESM）和对比增强磁共振成像（CE-MRI）在评估乳腺癌新辅助治疗病理反应中的诊断性能：一项系统评价和荟萃分析
Br J Radiol. 2020 Aug;93(1112):20200301. doi: 10.1259/bjr.20200301. Epub 2020 Jul 2.
5
Response to immunohistochemical markers' conversion after neoadjuvant chemotherapy in breast cancer patients: association between imaging and histopathologic analysis.乳腺癌患者新辅助化疗后免疫组化标志物转化的反应：影像学与组织病理学分析的相关性。
Clin Transl Oncol. 2020 Jan;22(1):91-102. doi: 10.1007/s12094-019-02112-z. Epub 2019 Apr 20.
6
Drug Combinations in Breast Cancer Therapy.乳腺癌治疗中的药物联合应用
Pharm Nanotechnol. 2019;7(1):3-23. doi: 10.2174/2211738507666190122111224.
7
Intravoxel incoherent motion (IVIM) histogram biomarkers for prediction of neoadjuvant treatment response in breast cancer patients.用于预测乳腺癌患者新辅助治疗反应的体素内不相干运动（IVIM）直方图生物标志物。
Eur J Radiol Open. 2017 Aug 18;4:101-107. doi: 10.1016/j.ejro.2017.07.002. eCollection 2017.
8
Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy.阴性淋巴结数量作为接受新辅助化疗的ypN0-N1期乳腺癌患者的预后因素
Tumour Biol. 2016 Jun;37(6):8445-54. doi: 10.1007/s13277-015-4640-3. Epub 2016 Jan 5.
9
Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration.乳腺癌新辅助化疗后生物标志物谱的改变：应考虑肿瘤异质性。
Oncotarget. 2015 Nov 3;6(34):36894-902. doi: 10.18632/oncotarget.5050.
10
Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival.患有大型（≥3厘米）局部晚期乳腺癌（T3、4、N1、2、M0）且正在接受新辅助化疗（NAC：环磷酰胺、阿霉素、多西他赛）的女性：添加卡培他滨可提高4年无病生存率。
Springerplus. 2015 Jan 13;4(1):9. doi: 10.1186/2193-1801-4-9. eCollection 2015.